Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Enliven Therapeutics (ELVN) Return on Capital Employed (2020 - 2026)

Enliven Therapeutics has reported Return on Capital Employed over the past 7 years, most recently at 3.9% for Q1 2026.

  • Quarterly results put Return on Capital Employed at 3.9% for Q1 2026, up 3283.0% from a year ago — trailing twelve months through Mar 2026 was 3.9% (up 3283.0% YoY), and the annual figure for FY2025 was 5.66%, up 3129.0%.
  • Return on Capital Employed reached 3.9% in Q1 2026 per ELVN's latest filing, up from 4.66% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 3.9% in Q1 2026 and bottomed at 71.52% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 32.98% (2024), compared with a mean of 35.2%.
  • The largest annual shift saw Return on Capital Employed crashed -1259bps in 2022 before it soared 4530bps in 2023.
  • Over 5 years, Return on Capital Employed stood at 63.09% in 2022, then soared by 46bps to 33.81% in 2023, then fell by -3bps to 34.89% in 2024, then surged by 87bps to 4.66% in 2025, then rose by 16bps to 3.9% in 2026.
  • Business Quant data shows Return on Capital Employed for ELVN at 3.9% in Q1 2026, 4.66% in Q4 2025, and 23.26% in Q3 2025.